Abstract
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Stereotactic body irradiation offers a non-invasive treatment modality for patients with early stage NSCLC who are not amenable to surgery or other invasive approaches because of their poor medical condition. Patients and Methods: Forty-three inoperable patients with NSCLC were treated with SBRT at our institution. A mean total dose of 30.5 Gy in 1-4 fractions was applied. The median follow-up duration was 14 months (range 6-36 months). Results: The actuarial survival at two years was 53%: two patients died from cancer progression whereas a further 8 patients died from comorbidities. Acute toxicity was practically absent, with 7 (16.3%) patients suffering from grade 1 symptoms and two from (4.6%) grade II effects. At the time of this report, only 1 patient had grade II and 6 patients (13.9%) grade I chronic symptoms. Conclusion: Our results compare favourably with recently published studies and confirm that stereotactic radiotherapy has the potential to produce high local control rates with a low risk of lung toxicity in patients not amenable to curative resection. The low grade of side-effects is encouraging for shortening the treatment using a greater dose per fraction.
| Original language | English |
|---|---|
| Pages (from-to) | 3615-3619 |
| Number of pages | 5 |
| Journal | Anticancer Research |
| Volume | 27 |
| Issue number | 5 B |
| Publication status | Published - Sep 2007 |
Fingerprint
Keywords
- Normal tissue toxicity
- NSCLC
- Radiotherapy
- SBRT
- Tumour response
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer. / Scorsetti, Marta; Navarria, P.; Facoetti, A.; Lattuada, P.; Urso, G.; Mirandola, A.; Ferraroli, G. M.; Alloisio, M.; Ravasi, G.
In: Anticancer Research, Vol. 27, No. 5 B, 09.2007, p. 3615-3619.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer
AU - Scorsetti, Marta
AU - Navarria, P.
AU - Facoetti, A.
AU - Lattuada, P.
AU - Urso, G.
AU - Mirandola, A.
AU - Ferraroli, G. M.
AU - Alloisio, M.
AU - Ravasi, G.
PY - 2007/9
Y1 - 2007/9
N2 - Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Stereotactic body irradiation offers a non-invasive treatment modality for patients with early stage NSCLC who are not amenable to surgery or other invasive approaches because of their poor medical condition. Patients and Methods: Forty-three inoperable patients with NSCLC were treated with SBRT at our institution. A mean total dose of 30.5 Gy in 1-4 fractions was applied. The median follow-up duration was 14 months (range 6-36 months). Results: The actuarial survival at two years was 53%: two patients died from cancer progression whereas a further 8 patients died from comorbidities. Acute toxicity was practically absent, with 7 (16.3%) patients suffering from grade 1 symptoms and two from (4.6%) grade II effects. At the time of this report, only 1 patient had grade II and 6 patients (13.9%) grade I chronic symptoms. Conclusion: Our results compare favourably with recently published studies and confirm that stereotactic radiotherapy has the potential to produce high local control rates with a low risk of lung toxicity in patients not amenable to curative resection. The low grade of side-effects is encouraging for shortening the treatment using a greater dose per fraction.
AB - Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Stereotactic body irradiation offers a non-invasive treatment modality for patients with early stage NSCLC who are not amenable to surgery or other invasive approaches because of their poor medical condition. Patients and Methods: Forty-three inoperable patients with NSCLC were treated with SBRT at our institution. A mean total dose of 30.5 Gy in 1-4 fractions was applied. The median follow-up duration was 14 months (range 6-36 months). Results: The actuarial survival at two years was 53%: two patients died from cancer progression whereas a further 8 patients died from comorbidities. Acute toxicity was practically absent, with 7 (16.3%) patients suffering from grade 1 symptoms and two from (4.6%) grade II effects. At the time of this report, only 1 patient had grade II and 6 patients (13.9%) grade I chronic symptoms. Conclusion: Our results compare favourably with recently published studies and confirm that stereotactic radiotherapy has the potential to produce high local control rates with a low risk of lung toxicity in patients not amenable to curative resection. The low grade of side-effects is encouraging for shortening the treatment using a greater dose per fraction.
KW - Normal tissue toxicity
KW - NSCLC
KW - Radiotherapy
KW - SBRT
KW - Tumour response
UR - http://www.scopus.com/inward/record.url?scp=35349015811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35349015811&partnerID=8YFLogxK
M3 - Article
C2 - 17972525
AN - SCOPUS:35349015811
VL - 27
SP - 3615
EP - 3619
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 5 B
ER -